103 studies found for:    MUC1
Show Display Options
Rank Status Study
1 Active, not recruiting A Study Evaluating Vaccination of Prostate Cancer Patients With Self Dendritic Cells Expressing MUC1
Condition: Prostate Cancer
Intervention: Biological: DC-Tn-MUC1: autologous dendritic cells expressing Tn-MUC1
2 Completed
Has Results
Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma
Condition: Risk for Colorectal Cancer
Intervention: Biological: MUC1 - Poly ICLC
3 Not yet recruiting Safety Study of Human MUC-1 (Mucin-1) Adenoviral Vector Vaccine for Immunotherapy of Epithelial Cancers
Condition: Epithelial Cancers of the Lung, Breast, Ovary, Prostate and Colon
Intervention: Drug: Ad-sig-hMUC-1/ecdCD40L vector vaccine
4 Recruiting Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer (NSCLC)
Intervention: Biological: Vaccine + PolyICLC
5 Suspended Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps
Condition: Adenomatous Polyp
Interventions: Biological: MUC1 peptide-poly-ICLC adjuvant vaccine;   Other: placebo;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
6 Unknown  Nasal Mucin Oral Supplementation Treatment Respiratory Inflammation Using PUFA in Cystic Fibrosis (CF) Patients
Conditions: Cystic Fibrosis;   Dietary Modification
Interventions: Other: polyunsaturated fatty acids n-3;   Other: Poly Unsaturated Fatty Acid
7 Withdrawn A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies
Conditions: Multiple Myeloma;   Tumors
Intervention: Biological: Peptide Vaccine (MUC-1)
8 Active, not recruiting MUC1 Vaccine for Triple-negative Breast Cancer
Conditions: Breast Cancer;   Inflammatory Breast Cancer;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Biological: MUC-1 peptide vaccine;   Biological: poly ICLC;   Biological: MUC1 peptide-poly-ICLC adjuvant vaccine;   Other: laboratory biomarker analysis;   Other: enzyme-linked immunosorbent assay;   Other: flow cytometry
9 Terminated Vaccine Therapy in Treating Patients With Metastatic Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: recombinant vaccinia-MUC1 vaccine;   Biological: recombinant vaccinia-TRICOM vaccine;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
10 Completed A Study to Assess the Safety and Efficacy of MUC1 Peptide Vaccine and hGM-CSF in Patients With MUC1-positive Tumor Malignancies
Condition: Multiple Myeloma
Intervention: Biological: ImMucin, hGM-CSF
11 Active, not recruiting MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: MUC_1
12 Recruiting Mucin Glycosylating Enzymes in Head and Neck Cancers
Condition: Mucin Glycosylating Enzyme, HNSCC
Intervention:
13 Terminated Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer
Condition: Prostatic Neoplasms
Intervention: Biological: MVA-MUC1-IL2
14 Withdrawn Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer (NSCLC) Stage III
Interventions: Other: Biological: MUC1 peptide specific immunotherapy;   Drug: Cyclophosphamide (CPA)
15 Completed Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Biological: MVA-MUC1-IL2;   Drug: 1st line Chemotherapy
16 Completed Vaccine Therapy in Treating Patients With Breast Cancer
Condition: Breast Cancer
Intervention: Biological: MUC1-KLH vaccine/QS21
17 Completed Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer
Condition: Prostate Cancer
Intervention: Biological: MUC1-KLH vaccine/QS21
18 Enrolling by invitation Mucin Concentration in Sputum From COPD Patients During a Pulmonary Exacerbation
Condition: COPD
Intervention: Other: sputum collection
19 Recruiting Assessing Response to Neoadjuvant Chemotherapy With HD PET/CT, Serum Glycomic Markers and Tissue Muc-1 Isoforms
Condition: Breast Cancer
Intervention: Other: PET CT imaging
20 Not yet recruiting A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia, in Relapse;   Recurrent Adult Acute Myeloid Leukemia
Intervention: Drug: GO-203-2c

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years